CareRx Reports Results for the Second Quarter of 2025

Core Insights - CareRx Corporation reported its financial results for the second quarter of 2025, highlighting a revenue of $91.4 million, an increase from the previous quarter but a slight decrease compared to the same quarter in 2024 [2][3] - The company experienced growth in the average number of beds serviced, which is expected to drive future growth [3] - Adjusted EBITDA for the quarter was $8.0 million, reflecting operational efficiencies and cost-saving initiatives [3][5] Financial Performance - Revenue for Q2 2025 was $91.4 million, compared to $89.6 million in Q1 2025 and $92.0 million in Q2 2024 [3][5] - Adjusted EBITDA for Q2 2025 was $8.0 million, up from $7.8 million in Q1 2025 and $7.5 million in Q2 2024 [3][5] - Net income for Q2 2025 was $0.6 million, an increase from $0.2 million in Q1 2025 and a recovery from a net loss of $1.4 million in Q2 2024 [3][5] Operational Highlights - The company ended the quarter with a bed count of 91,062, indicating growth in service capacity [2][3] - The increase in revenue compared to Q1 2025 was attributed to a higher average number of beds serviced and an additional weekday in the quarter [3] - The decrease in revenue compared to Q2 2024 was mainly due to a shift in the mix of branded and generic pharmaceuticals dispensed [3] Strategic Outlook - The CEO emphasized a focus on operational discipline and targeted investments to support home operator partners and enhance care quality [3] - The Ontario Ministry of Health's decision to pause changes to long-term care pharmacy funding is expected to have a positive impact on the company's financial outlook [4]